Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation

COPENHAGEN, Denmark, March 26, 2018 /CNW/ -- Genmab A/S (CPH: GEN, OTC:GMXAY), focused on the creation and development of differentiated antibody therapeutics for the treatment of cancer, today announced that their March 22^nd presentation from Genmab's Senior Vice President, IR & Communications, Rachel Curtis Gravesen, is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.

LINK:    https://tinyurl.com/dbvic03postpr

Genmab A/S' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX^® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra^® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody^® platform for generation of bispecific antibodies, and the HexaBody^® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

View original content:http://www.prnewswire.com/news-releases/genmab-as-webcast-presentation-now-available-for-on-demand-viewing-dbvic---deutsche-bank-adr-virtual-investor-conference-300619201.html

SOURCE Genmab A/S